Literature DB >> 19687425

Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.

Heidi H Kong1, Howard A Fine, Jere B Stern, Maria L Chanco Turner.   

Abstract

BACKGROUND: Photosensitivity has been reported in patients who were treated with vandetanib (ZD6474), an inhibitor of epidermal growth factor receptor, vascular endothelial growth factor receptor, and the RET (rearranged during transfection) kinases. OBSERVATIONS: We describe the occurrence of cutaneous hyperpigmentation after photosensitivity in 2 patients who were treated with vandetanib. The pigmentation patterns were variable within and between patients. Biopsy specimens from different sites revealed variability in Perls and Fontana staining patterns.
CONCLUSIONS: These 2 cases highlight the unusual occurrence of cutaneous hyperpigmentation after vandetanib-associated photosensitivity, a reaction that demonstrates that medications are important causes of acquired photosensitivity and hyperpigmentation. Aggressive photoprotection may facilitate the resolution of diffuse hyperpigmentation. Dermatologists should endeavor to identify and report novel cutaneous adverse effects as new targeted therapies are developed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19687425      PMCID: PMC3521518          DOI: 10.1001/archdermatol.2009.177

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  6 in total

Review 1.  Cutaneous side-effects of kinase inhibitors and blocking antibodies.

Authors:  Caroline Robert; Jean-Charles Soria; Alain Spatz; Axel Le Cesne; David Malka; Patricia Pautier; Janine Wechsler; Catherine Lhomme; Bernard Escudier; Valérie Boige; Jean-Pierre Armand; Thierry Le Chevalier
Journal:  Lancet Oncol       Date:  2005-07       Impact factor: 41.316

Review 2.  Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment.

Authors:  O Dereure
Journal:  Am J Clin Dermatol       Date:  2001       Impact factor: 7.403

3.  The effects of ZD6474, an inhibitor of VEGF signaling, on cutaneous wound healing in mice.

Authors:  Jason Ko; Joel Ross; Hani Awad; Herbert Hurwitz; Bruce Klitzman
Journal:  J Surg Res       Date:  2005-09-02       Impact factor: 2.192

4.  A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.

Authors:  Tomohide Tamura; Hironobu Minami; Yasuhide Yamada; Noboru Yamamoto; Tatsu Shimoyama; Haruyasu Murakami; Atsushi Horiike; Yasuhito Fujisaka; Tetsu Shinkai; Makoto Tahara; Kenji Kawada; Hiromichi Ebi; Yasutsuna Sasaki; Haiyi Jiang; Nagahiro Saijo
Journal:  J Thorac Oncol       Date:  2006-11       Impact factor: 15.609

5.  A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.

Authors:  Katsuyuki Kiura; Kazuhiko Nakagawa; Tetsu Shinkai; Kenji Eguchi; Yuichiro Ohe; Nobuyuki Yamamoto; Masahiro Tsuboi; Soichiro Yokota; Takashi Seto; Haiyi Jiang; Kazuto Nishio; Nagahiro Saijo; Masahiro Fukuoka
Journal:  J Thorac Oncol       Date:  2008-04       Impact factor: 15.609

6.  Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

Authors:  John V Heymach; Bruce E Johnson; Diane Prager; Edit Csada; Jaromír Roubec; Milos Pesek; Irena Spásová; Chandra P Belani; István Bodrogi; Shirish Gadgeel; Sarah J Kennedy; Jeannie Hou; Roy S Herbst
Journal:  J Clin Oncol       Date:  2007-09-20       Impact factor: 44.544

  6 in total
  11 in total

Review 1.  Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Authors:  Julia Dai; Viswanath R Belum; Shenhong Wu; Vincent Sibaud; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2017-09-14       Impact factor: 11.527

2.  A severe photosensitivity dermatitis caused by crizotinib.

Authors:  Matthew G Oser; Pasi A Jänne
Journal:  J Thorac Oncol       Date:  2014-07       Impact factor: 15.609

3.  Development of Photoonycholysis with Vandetanib Therapy.

Authors:  Miruna Negulescu; Slimane Zerdoud; Serge Boulinguez; Emilie Tournier; Jean-Pierre Delord; Robert Baran; Vincent Sibaud
Journal:  Skin Appendage Disord       Date:  2016-11-03

4.  Successful laser treatment of vandetanib-associated cutaneous pigmentation.

Authors:  Sara Brooks; W Marston Linehan; Ramaprasad Srinivasan; Heidi H Kong
Journal:  Arch Dermatol       Date:  2011-03

5.  Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel.

Authors:  Young-Min Son; Joo-Young Roh; Eun-Kyung Cho; Jong-Rok Lee
Journal:  Ann Dermatol       Date:  2011-12-27       Impact factor: 1.444

6.  Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.

Authors:  Jennifer Goldstein; Anisha B Patel; Jonathan L Curry; Vivek Subbiah; Sarina Piha-Paul
Journal:  BMC Dermatol       Date:  2015-02-13

7.  A rare case of late-onset lichenoid photodermatitis after vandetanib therapy.

Authors:  James Bota; Valerie Harvey; Cynthia Ferguson; Antoinette Hood
Journal:  JAAD Case Rep       Date:  2015-05-25

8.  Dermoscopic findings of perifollicular pigmentation associated with vandetanib.

Authors:  Jade Cury-Martins; Jose Antonio Sanches
Journal:  Dermatol Pract Concept       Date:  2018-10-31

9.  Blue-grey hyperpigmentation in acne after vandetanib therapy and doxycycline use: A case report.

Authors:  Jonah W Perlmutter; Rachel C Cogan; Marni C Wiseman
Journal:  SAGE Open Med Case Rep       Date:  2022-03-22

Review 10.  Anticancer treatments and photosensitivity.

Authors:  V Sibaud
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-06       Impact factor: 9.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.